Edwards Lifesciences (NYSE:EW) Stock Gets Price Target Boost from Leerink Partners

Edwards Lifesciences (NYSE:EW) had its price objective lifted by investment analysts at Leerink Partners from $101.00 to $112.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the medical research company’s stock. Leerink Partners‘s price objective points to a potential upside of 11.68% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the stock. UBS Group reaffirmed a “buy” rating and issued a $110.00 price target (up from $90.00) on shares of Edwards Lifesciences in a report on Thursday, October 8th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a report on Thursday, October 15th. Wall Street Zen downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, October 31st. Piper Sandler reissued an “overweight” rating and issued a $115.00 target price (up from $101.00) on shares of Edwards Lifesciences in a research report on Thursday. Finally, Truist Financial set a $113.00 target price on Edwards Lifesciences and gave the company a “buy” rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average price target of $106.52.

Edwards Lifesciences Stock Performance

NYSE EW traded up $0.92 during trading hours on Thursday, reaching $100.29. 5,753,558 shares of the company were exchanged, compared to its average volume of 4,514,993. Edwards Lifesciences has a 1 year low of $74.66 and a 1 year high of $104.17. The business’s 50 day simple moving average is $88.48 and its 200-day simple moving average is $85.61. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $57.75 billion, a P/E ratio of 57.54, a P/E/G ratio of 2.49 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Wednesday, November 4th. The medical research company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.74 by $0.06. The business had revenue of $1.72 billion for the quarter, compared to analyst estimates of $1.68 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.67 earnings per share. On average, equities research analysts expect that Edwards Lifesciences will post 3.00 earnings per share for the current year.

Insiders Place Their Bets

In other news, VP Annette Brüls sold 2,644 shares of the firm’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president directly owned 17,984 shares of the company’s stock, valued at $1,618,200.32. This trade represents a 12.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel Lippis sold 619 shares of Edwards Lifesciences stock in a transaction on Thursday, October 8th. The shares were sold at an average price of $85.65, for a total value of $53,017.35. Following the completion of the transaction, the vice president owned 40,034 shares of the company’s stock, valued at approximately $3,428,912.10. This trade represents a 1.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 5,045 shares of company stock worth $451,596 over the last 90 days. Corporate insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in Edwards Lifesciences during the second quarter valued at approximately $5,318,092,000. Bank of New York Mellon Corp bought a new position in shares of Edwards Lifesciences in the second quarter worth $1,274,082,000. Bank of America Corp DE bought a new stake in Edwards Lifesciences during the second quarter valued at $605,397,000. Deutsche Bank AG purchased a new position in Edwards Lifesciences during the second quarter worth about $516,552,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Edwards Lifesciences by 0.6% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,488,643 shares of the medical research company’s stock valued at $496,503,000 after acquiring an additional 30,495 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Trending Headlines about Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards reported third-quarter adjusted EPS of $0.80 and revenue of $1.72 billion, topping estimates. Sales grew 11.2% year over year, supported by 8.8% growth in TAVR and a 45.6% surge in transcatheter mitral and tricuspid therapies (TMTT). The company raised its full-year adjusted EPS outlook to $2.97–$3.05, reinforcing expectations for continued growth. Q3 earnings call highlights
• Positive Sentiment: New PROGRESS Trial results found TAVR performed better than active surveillance for at-risk patients with moderate aortic stenosis, including fewer combined death or heart-failure outcomes, fewer heart-failure hospitalizations and improved quality of life. The findings could support earlier use of the procedure; the company also expects procedure volumes to benefit from expanded Medicare reimbursement. PROGRESS Trial data
• Positive Sentiment: Several firms raised price targets after the results. Piper Sandler and BTIG set targets of $115, Baird upgraded EW to “outperform” with a $116 target, and JPMorgan raised its target to $120. These actions signal improved analyst expectations. JPMorgan price target change
• Negative Sentiment: Management cautioned that more competition is coming in TAVR, which could pressure market share or pricing. RBC also said the PROGRESS findings may not meaningfully expand the TAVR market, tempering expectations for the trial’s commercial impact. CEO comments on TAVR competition

About Edwards Lifesciences

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.